Wednesday July 26th 2017

FDA delays decision on Biogen’s multiple sclerosis drug

(Reuters) – Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company’s multiple sclerosis drug by three months to evaluate the application. (Source: Reuters: Health)

See the article here – 

FDA delays decision on Biogen’s multiple sclerosis drug

Leave a Comment

More from category

Gait and cognitive impairments in multiple sclerosis: the specific contribution of falls and fear of falling – Kalron A, Allali G.
Gait and cognitive impairments in multiple sclerosis: the specific contribution of falls and fear of falling – Kalron A, Allali G.

Our goal was to identify the specific contribution of fear of falling (FoF) and falls with quantitative gait [Read More]

12 National Patient Advocacy Organizations Urge Senate to Vote “No” on Advancing ACA Repeal, Urging
12 National Patient Advocacy Organizations Urge Senate to Vote “No” on Advancing ACA Repeal, Urging

/About-the-Society/News/12-National-Patient-Advocacy-Organizations-Urge-Se [Read More]

Low vitamin D may affect recovery of injured corneas
Low vitamin D may affect recovery of injured corneas

Injury or disease in combination with too little vitamin D can be bad for the window to your eyes. The three-layer, [Read More]

CUMC researchers capture first snapshot of key brain receptor in action
CUMC researchers capture first snapshot of key brain receptor in action

Columbia University Medical Center researchers have captured the first three-dimensional snapshots of the AMPA-subtype [Read More]

Contact Your Senators About Health Care
Contact Your Senators About Health Care

/About-the-Society/News/Contact-Your-Senators-About-Health-Care [Read More]